Menu ×

HEALTHCARE & PHARMACEUTICAL

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Segmentation by Product (Assays/Biomarkers and Analyzers); by Disease Type (Ulcerative Colitis and Crohn’s Disease); by Disease Stage (Mild, Moderate, and Severe); by Test Type (Blood Tests, Stool Tests, Antibody Tests, and Biopsy); by Patient Demography (Pediatric, Adults, and Geriatric); by End-User (Hospitals, Clinics, Diagnostic Laboratories, & Others); and by Test Method – Global Demand Analysis & Opportunity Outlook 2019-2028

  • Text Size:

Extensive insights into the Growth of In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • July 12, 2021: Quidel Corporation announced that it has received the CE Mark for two of its products, namely, Savanna multiplex molecular analyzer and Savanna RVP4 Assay (Respiratory Viral Panel-4). The Savanna system, which is an automated in-vitro diagnostic platform, can now be sold in the markets of Europe and other countries where the CE Mark is accepted.

Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Highlights Over 2019 - 2028

asThe global in-vitro inflammatory bowel disease (IBD) market is estimated to garner a revenue of USD 2391.64 Million by the end of 2028, up from USD 1640 Million in 2019, by growing at a CAGR of 5.4% over the forecast period, i.e., 2021 – 2028. The growth of the market can be primarily attributed to the growing prevalence of inflammatory bowel disease worldwide, and therefore the need amongst individuals to diagnose the disease. According to the statistical report titled “The Global, Regional and National Burden of Inflammatory Bowel Disease in 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017”, the prevalence of IBD globally in the year 2017 recorded to 6.8 Million. Further, the statistics also stated that the age-standardized prevalence rate of the disease touched 84.3 per 100000 population in the year 2017, as compared to 79.5 per 100000 population in the year 1990. Moreover, the market is also anticipated to grow on account of the growing healthcare expenditure and the rising research activities in the field of gastro sciences.

In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market GraphThe global in-vitro inflammatory bowel disease (IBD) market is also expected to grow on account of the growing concern for the increasing incidences of digestive diseases worldwide and the increasing awareness amongst individuals to treat such diseases. According to the statistics by the Institute for Health Metrics and Evaluation (IHME), deaths caused due to digestive diseases around the globe increased from 726331.36 deaths in the year 2000 to 939281 deaths in the year 2019. CLICK TO DOWNLOAD SAMPLE REPORT

Deaths due to Digestive Diseases Graph

Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Regional Synopsis

Regionally, the global in-vitro inflammatory bowel disease (IBD) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to hold the highest market share throughout the forecast period, backed by the increasing prevalence of IBD amongst the individuals in the region, followed by the presence of a strong healthcare network in countries such as the United States, as well as for the rising healthcare expenditure in the countries in the region. The market in the region garnered a revenue of USD 723.24 Million in the year 2019, and it is further expected to reach USD 1067.01 Million by the end of 2028. The market in the region is also anticipated to grow with the highest CAGR of 5.7% during the forecast period. 

On the other hand, the market in Europe is expected to hold the second-leading market share and attain a revenue of USD 915.66 Million by the end of 2028. Amongst the countries in the region, the market in Germany is anticipated to garner the second-largest revenue of USD 165.08 Million by the end of 2028, up from a revenue of USD 110.09 Million in 2019.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Growth Drivers and Challenges Impacting the Growth of the Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market

Growth Drivers

  • Increasing Prevalence of IBD
  • Rapid Research and Development in Gastro Sciences

Challenges

  • Stringent Product Approval Process

Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market Segmentation Synopsis

The global in-vitro inflammatory bowel disease (IBD) diagnostic market is segmented by product into assays/biomarkers and analyzers. Out of these, the assays/biomarkers segment is anticipated to hold the highest market share throughout the forecast period. The segment is also anticipated to grow with the highest CAGR of 5.6% during the forecast period. Further, on the basis of disease type, the market is segmented into ulcerative colitis and Crohn’s disease, out of which, the ulcerative colitis segment is anticipated to hold the highest market share and also grow with the highest CAGR of 5.7% during the forecast period. Based on disease stage, the market is segmented into mild, moderate, and severe, out of which, the severe segment is anticipated to hold the largest market revenue of USD 1225.89 Million by the end of 2028, up from a revenue of USD 823.27 Million in 2019. Further, on the basis of test type, the market is segmented into blood tests, stool tests, antibody tests, and biopsy. Out of these segments, the blood tests segment is anticipated to hold the highest market share and also attain a market revenue of USD 931.51 Million by the end of 2028. On the basis of patient demography, the market is segmented into pediatric, adults, and geriatric, out of which, the adults segment is anticipated to hold the largest revenue of USD 1592.15 Million by the end of 2028. The market is also segmented on the basis of end-user into hospitals, clinics, diagnostic laboratories, and others. Out of these segments, the hospitals segment is projected to hold the highest market share and also attain a revenue of USD 1297.52 Million by the end of 2028. Moreover, on the basis of test method, the market is segmented into PETIA, ELISA, rapid, and others, out of which, the ELISA segment is expected to garner the highest market revenue of USD 663.62 Million by the end of 2028, up from a revenue of USD 428.08 Million in 2019.

Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global in-vitro inflammatory bowel disease (IBD) market that are included in our report are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, BioSystems S.A., Inova Diagnostics, Inc. (Werfen), and others.

Key Reasons to Buy Our Report

  • The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
  • It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
  • The report includes detailed company profiles of the major players dominating the market.
  • We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
  • We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.

FREQUENTLY ASKED QUESTIONS

Global In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market TOC

  1. Introduction
    1. Market Definition
    2. Market Segmentation
    3. Product overview
  2. Assumptions and Market Estimation Caveat
  3. Research Methodology
    1. Research process
    2. Primary research
    3. Secondary research
  4. Executive Summary - In-vitro Inflammatory Bowel Disease (IBD) Diagnostic Market
  5. Analysis of Market Dynamics
    1. Growth Drivers  
    2. Market Trends
    3. Growth Opportunities
    4. Restraints
  6. Regulatory & Standards Landscape
  7. Impact of COVID-19 on the In-vitro Inflammatory Bowel Disease (IBD) Diagnostic Market
    1. Impact on the Overall Market
    2. Impact on the Demand
    3. Impact on the Consumption
    4. Impact on the Drugs Manufacturers
    5. Impact on the Supply & Distribution
    6. Impact on the Key Market Players
    7. Impact on the Pricing
  8. Market Impact Analysis in 2020 (Quarter Wise) w.r.t COVID-19 Pandemic (USD Million)
  9. Pricing Analysis
  10. Analysis on the End-user
  11. Epidemiology Analysis
  12. Competitive Structure
    1. For In-Vitro Diagnostic Market
    2. Market Share Analysis, 2020
  13. In-Vitro Inflammatory Bowel Disease Diagnostic Market Segmentation
    1. By Product
      1. Assays/Biomarkers
      2. Analyzers
    2. By Disease Type
      1. Ulcerative Colitis
      2. Crohn’s Disease
    3. By Disease Stage
      1. Mild
      2. Moderate
      3. Severe
    4. By Test Type
      1. Blood Tests
      2. Stool Tests
      3. Antibody Tests
      4. Biopsy
    5. By Patient Demography
      1. Pediatric
      2. Adults
      3. Geriatric
    6. By End-User
      1. Hospitals
      2. Clinics
      3. Diagnostic Laboratories
      4. Others
    7. By Test Method
      1. PETIA
      2. ELISA
      3. Rapid
      4. Others
    8. By Region
      1. North America, 2019-2028F (USD Million)
      2. Latin America, 2019-2028F (USD Million)
      3. Europe, 2019-2028F (USD Million)
      4. Asia-Pacific, 2019-2028F (USD Million)
      5. Middle East & Africa, 2019-2028F (USD Million)
  14. North America, 2019-2028F (USD Million)
    1. Leading Companies in In-Vitro Inflammatory Bowel Disease Diagnostic Market
    2. Pricing Outlook (USD)
    3. Reimbursement and Payment Policies, by Country
    4. End-User Analysis
    5. Analysis on the Annual Test Quantity
    6. Analysis on Test Methods
    7. Distributor Outlook
    8. Market by Value (USD Million)
    9. Market Segmentation
    10. By Product
      1. Assays/Biomarkers
      2. Analyzers
    11. By Disease Type
      1. Ulcerative Colitis
      2. Crohn’s Disease
    12. By Disease Stage
      1. Mild
      2. Moderate
      3. Severe
    13. By Test Type
      1. Blood Tests
      2. Stool Tests
      3. Antibody Tests
      4. Biopsy
    14. By Patient Demography
      1. Pediatric
      2. Adults
      3. Geriatric
    15. By End-User
      1. Hospitals
      2. Clinics
      3. Diagnostic Laboratories
      4. Others
    16. By Test Method
      1. PETIA
      2. ELISA
      3. Rapid
      4. Others
    17. Country
      1. United States
      2. Canada
      3. Mexico
  15. Latin America, 2019-2028F (USD Million)
    1. Market by Value (USD Million)
    2. Market Segmentation
      1. By Product
      2. By Disease Type
      3. By Disease Stage
      4. By Test Type
      5. By Patient Demography
      6. By End-User
      7. By Test Method
      8. By Country
        1. Brazil
        2. Argentina
        3. Colombia
        4. Rest of LATAM
  16. Europe, 2019-2028F (USD Million)
    1. Market by Value (USD Million)
    2. Market Segmentation
      1. By Product
      2. By Disease Type
      3. By Disease Stage
      4. By Test Type
      5. By Patient Demography
      6. By End-User
      7. By Test Method
      8. By Country
        1. France
        2. Italy
        3. Spain
        4. Germany
        5. United Kingdom
        6. Russia
        7. Rest of Europe
  17. Asia-Pacific, 2019-2028F (USD Million)
    1. Market by Value (USD Million)
    2. Market Segmentation
      1. By Product
      2. By Disease Type
      3. By Disease Stage
      4. By Test Type
      5. By Patient Demography
      6. By End-User
      7. By Test Method
      8. By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. South Korea
        6. Indonesia
        7. Rest of APAC
  18. Middle East & Africa, 2019-2028F (USD Million)
    1. Market by Value (USD Million)
    2. Market Segmentation
      1. By Product
      2. By Disease Type
      3. By Disease Stage
      4. By Test Type
      5. By Patient Demography
      6. By End-User
      7. By Test Method
      8. By Country
        1. South Africa
        2. GCC
        3. Nigeria
        4. Rest of MEA

Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved